ACTG

Acacia Research Corp. 10-Q Summary (Period Ended June 30, 2003)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2003, for Acacia Research Corporation, a Delaware corporation. The company operates two distinct business groups: the CombiMatrix group (life sciences, focusing on DNA synthesis on semiconductor chips) and the Acacia Technologies group (media technologies, focusing on Digital Media Transmission (DMT) and V-chip patents). Following a December 2002 recapitalization, the company issues two classes of common stock (AR-CombiMatrix and AR-Acacia Technologies) to reflect the separate performance of these divisions, though they remain a single legal entity.

Key Financial Metrics

Segment Performance (Six Months Ended June 30, 2003):

• CombiMatrix Group: Net loss of $(10,370); Revenues of $222 (primarily product sales and contract revenue).
• Acacia Technologies Group: Net loss of $(3,071); Revenues of $25 (entirely from license fee income).

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 64% year-over-year (from $687k to $247k). This was driven by the completion of government grants (SBIR/NIH) in 2002 and a reduction in product sales volume compared to the prior year.
• Expense Reduction: Operating expenses decreased significantly from $22.2 million to $14.1 million. Research and Development (R&D) expenses dropped 42% (from $7.7M to $4.5M) due to the achievement of milestones in the Roche agreement. Marketing, General, and Administrative (MG&A) expenses fell 19% due to reduced legal costs related to the 2002 recapitalization and lower personnel overhead.
• Improved Cash Flow: Net cash used in operating activities improved substantially, decreasing from $13.6 million in 2002 to $4.0 million in 2003. This improvement was primarily due to an $8.1 million increase in deferred revenues from milestone payments received from Roche and Toppan Printing Corporation.
• Minority Interests: Minority interest in losses dropped from $6.5 million in 2002 to $30k in 2003, as the company acquired 100% ownership of CombiMatrix Corporation in December 2002.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• CombiMatrix: Management expects R&D expenses to remain volatile. Significant milestones were achieved with Roche, and a new strategic alliance with Toppan Printing Corporation was signed in May 2003, including a $1.0 million upfront payment. The group launched "Express Track," a drug discovery program for siRNA molecules.
• Acacia Technologies: The group has entered into 27 DMT license agreements since November 2002, including a significant deal with LodgeNet Entertainment. The V-chip patent expired in July 2003; future revenue depends on the commercialization of DMT technology and ongoing litigation.
• Liquidity: The company raised $4.9 million in net proceeds from a private equity financing in May 2003. Management believes current cash, short-term investments, and anticipated cash flows are sufficient for the foreseeable future, though future capital requirements for CombiMatrix are substantial.

Risks and Contingencies:

• Patent Litigation: Acacia Technologies initiated DMT infringement litigation against ~40 defendants in February 2003. Conversely, a summary judgment was granted against Soundview Technologies regarding V-chip infringement in September 2002; the company intends to appeal.
• Capital Needs: The CombiMatrix group faces substantial long-term capital requirements for R&D and commercialization. Failure to raise additional capital could force curtailment of operations.
• Two-Class Stock Structure: Risks exist regarding the allocation of assets, liabilities, and corporate opportunities between the two groups, which could adversely affect one class of stockholders.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the timing of revenue recognition for the $8.1 million in deferred revenues from Roche and Toppan, as this significantly impacts future cash flow projections.
• Patent Expiration Impact: Assess the financial impact of the V-chip patent expiration (July 2003) on the Acacia Technologies group's recurring revenue stream.
• Litigation Outcomes: Monitor the status of the DMT infringement lawsuits and the appeal of the V-chip summary judgment, as these are critical to the Acacia Technologies group's valuation.
• R&D Milestone Dependency: Evaluate the CombiMatrix group's reliance on the Roche agreement for funding and future revenue, noting the volatility of milestone-based R&D expenses.
• Cash Burn Rate: Review the sustainability of the current cash position ($55.1 million total liquid assets) against the projected substantial capital requirements for CombiMatrix's commercialization efforts.